Literature DB >> 21327429

Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome.

Nada Vujasinovic-Stupar1, Nada Pejnovic, Ljiljana Markovic, Maja Zlatanovic.   

Abstract

Pregnancy-associated spinal osteoporosis (PPSO) is a rare condition characterized by severe back pain occurring near the end of the first pregnancy or shortly afterward. The aim of this report is to present a 12-year follow-up of a patient with PPSO. Also, the outcomes of patient's two pregnancies and her infants after long-term treatment with bisphosphonates are assessed. A young woman was referred to our tertiary care hospital aged 30 years, due to intense pain in thoracic and lumbar region that started during the last month of her first pregnancy and got worse after delivery. Bone mineral density (BMD) measurement, clinical, and biochemical parameters were performed. Extremely low lumbar spine BMD, L2-L4: 0.627 g/cm(2), T-score -4.8, Z-score -4.3, 52% young adult indicated severe osteoporosis. Cyclical treatment with etidronate and then pamidronate was started, and a substantial increase in the BMD and the reduction in back pain intensity were observed. An increase in BMD of 44.8% over baseline was observed after 12 years of follow-up. Her two pregnancies were uneventful, and no neonatal adverse effects were observed. Control DXA scan in her girl child aged 6.8 years revealed low BMD at the lumbar spine. As PPSO seems to be an underdiagnosed severe disease, caution is recommended if back pain occurs in the last trimester or early post-partum period. Although pre-pregnancy use of bisphosponates does not pose a substantial fetal risk, their use in women of childbearing age might best be done only when strong clinical indications exist.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327429     DOI: 10.1007/s00296-011-1816-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Bisphosphonates in pregnancy and lactation-associated osteoporosis.

Authors:  S M O'Sullivan; A B Grey; R Singh; I R Reid
Journal:  Osteoporos Int       Date:  2006-04-27       Impact factor: 4.507

Review 2.  Maternal and fetal outcome after long-term bisphosphonate exposure before conception.

Authors:  S Hassen-Zrour; W Korbâa; I Béjia; Z Saidani; N Bergaoui
Journal:  Osteoporos Int       Date:  2009-06-16       Impact factor: 4.507

3.  The effect of pregnancy on bone density and bone turnover.

Authors:  K E Naylor; P Iqbal; C Fledelius; R B Fraser; R Eastell
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

Review 4.  Maternity and bone mineral density.

Authors:  Magnus K Karlsson; Henrik G Ahlborg; Caroline Karlsson
Journal:  Acta Orthop       Date:  2005-02       Impact factor: 3.717

5.  Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.

Authors:  Serge C L M Cremers; Socrates E Papapoulos; Hans Gelderblom; Caroline Seynaeve; Jan den Hartigh; Pieter Vermeij; Carin C D van der Rijt; Lia van Zuylen
Journal:  J Bone Miner Res       Date:  2005-05-31       Impact factor: 6.741

6.  A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy.

Authors:  A J Black; J Topping; B Durham; R G Farquharson; W D Fraser
Journal:  J Bone Miner Res       Date:  2000-03       Impact factor: 6.741

Review 7.  Does treatment with bisphosphonates endanger the human pregnancy?

Authors:  Nada Djokanovic; Chagit Klieger-Grossmann; Gideon Koren
Journal:  J Obstet Gynaecol Can       Date:  2008-12

Review 8.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

9.  Pregnancy-associated osteoporosis: an underestimated and underdiagnosed severe disease. A review of two cases in short- and long-term follow-up.

Authors:  U C Stumpf; A A Kurth; J Windolf; W J Fassbender
Journal:  Adv Med Sci       Date:  2007       Impact factor: 3.287

10.  Pregnancy- and lactation-associated osteoporosis with severe vertebral deformities: can strontium ranelate be a new alternative for the treatment?

Authors:  Mine Durusu Tanriover; S Gul Oz; Tumay Sozen; Alpaslan Kilicarslan; Gulay Sain Guven
Journal:  Spine J       Date:  2008-09-14       Impact factor: 4.166

View more
  5 in total

1.  Long-term outcome of patients with pregnancy and lactation-associated osteoporosis (PLO) with a particular focus on quality of life.

Authors:  Martin Gehlen; Ana Doina Lazarescu; Christian Hinz; Michael Schwarz-Eywill; Michael Pfeifer; Subathira Balasingam; Anna Maier
Journal:  Clin Rheumatol       Date:  2019-08-29       Impact factor: 2.980

2.  Women With Pregnancy and Lactation-Associated Osteoporosis (PLO) Have Low Bone Remodeling Rates at the Tissue Level.

Authors:  Adi Cohen; Mafo Kamanda-Kosseh; David W Dempster; Hua Zhou; Ralph Müller; Elliott Goff; Ivelisse Colon; Mariana Bucovsky; Julie Stubby; Thomas L Nickolas; Emily M Stein; Robert R Recker; Joan M Lappe; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2019-07-26       Impact factor: 6.741

3.  Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2011-07-05       Impact factor: 2.423

4.  A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature.

Authors:  Yukio Nakamura; Mikio Kamimura; Shota Ikegami; Keijiro Mukaiyama; Masatoshi Komatsu; Shigeharu Uchiyama; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2015-09-07       Impact factor: 2.423

5.  Hypercalcemia in pregnancy - a multifaceted challenge: case reports and literature review.

Authors:  Evelyne Rey; Claude-Emilie Jacob; Maral Koolian; Francine Morin
Journal:  Clin Case Rep       Date:  2016-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.